Investor Presentation First Nine Months of 2023

Solid operating profit growth driven by Diabetes care 143 Investor presentation First nine months of 2023 Novo NordiskⓇ Operating profit Operating profit split by franchise DKK billion -4% 11% 3% 8% 28% Percent of sales 3% 6% 7% 13% 15% 80 60% 10% 20% 60 60 40 20 20 0 2018 CER: Constant exchange rates 2019 Operating profit Operating profit as % of sales 40% 80% 90% 20% 2022 Diabetes and Obesity care Rare disease 0% 2020 2021 2022 2018 Reported operating profit growth Operating profit growth at CER

View entire presentation